Hims & Hers Weight Loss review

Hims & Hers Weight Loss is a cash-pay telehealth membership, not an all-in medication subscription. You complete an online health intake, a state-licensed clinician reviews it, and some states or cases require an audio or video visit. If the clinician prescribes, the program adds monthly check-ins, unlimited in-app provider messaging, weight tracking, nutrition and exercise guidance, and a care team. Medication is a second subscription, and an active membership is required to keep it. That setup is convenient for someone comfortable managing care through an app and paying without insurance. It is a poor match for anyone expecting comprehensive primary care, guaranteed access to a specific drug, or routine face-to-face visits; the company says GLP-1 availability still varies by state.

The headline prices need arithmetic. As of July 2026, the membership costs $39 for month one and then $149 a month, while medication is extra. As of July 2026, the advertised medication-only starting prices are $149 a month for the Wegovy pill, Foundayo pill, or Ozempic pill; $199 for the Wegovy pen or injectable Ozempic; $299 for Zepbound vials or KwikPen; and $1,899 for Mounjaro or Zepbound. That makes first-month totals of at least $188, $238, $338, or $1,938, respectively, and ongoing totals of at least $298, $348, $448, or $2,048 a month as of July 2026. “From” matters: Hims says price can vary by treatment and dose, and medication may be billed monthly or upfront. The $39 price as of July 2026 is introductory, not the durable membership cost. Public weight-loss pages do not promise that required labs, if any, are included. A separate broad Labs by Hims plan costs $349 per year as of July 2026, but buyers should not assume that optional wellness-testing plan is part of weight-loss care.

The current advertised menu is primarily branded medication. Wegovy tablets and pens contain semaglutide; Zepbound products contain tirzepatide; and Foundayo is branded orforglipron. FDA has approved those brands for chronic weight management in their labeled populations. Ozempic products and Mounjaro are branded diabetes drugs, so use specifically for weight loss is outside their labeled indications and depends on the clinician’s judgment and Hims’ eligibility rules. Compounded semaglutide is the exception, not the public bargain it once was: in March 2026, Hims said it would stop advertising compounded GLP-1s and reserve access on a limited scale for patients whose needs cannot be met by approved products. Current support material still documents compounded semaglutide, but the main shopping page gives no new-customer price for it. That distinction is crucial. FDA does not approve compounded drugs or review them before sale for safety, effectiveness, or quality, and says they should be used only when an approved drug cannot meet a patient’s medical need. If a compounded option appears, verify the dispensing pharmacy, exact ingredient and concentration, whether semaglutide base rather than a salt is used, vial instructions, included supplies, and recurring price.

The strongest part of this offer is choice: oral and injectable branded GLP-1s sit in one intake flow, including the FDA-approved Foundayo pill, and ongoing app support is more concrete than a one-time prescription visit. The weakest part is price presentation. Nobody can know from the landing page which drug a clinician will offer, whether a starting price applies at the prescribed dose, whether a third-party pharmacy such as Gifthealth will bill separately, whether labs or a live visit will be required, or how much must be paid upfront. Before paying, get the exact product name, approval status, dose-specific medication price, membership renewal, medication billing cadence, dispensing pharmacy, lab responsibility, and cancellation dates in writing.

Use this sequence before entering payment details. It keeps program marketing, eligibility review and final billing terms separate.

The official Hims weight-loss page presents multiple medication paths and separates medication pricing from an active weight-loss membership. The 2026 company update also describes a shift toward broader FDA-approved medication access while limiting compounded semaglutide. That makes the service worth comparing, but only after you confirm the exact drug, formulation, dose path and pharmacy source.

The pricing headline can be easy to misread because medication and membership can be separate line items. A low monthly medication price may still require a recurring membership. The right comparison is total monthly cost after the first promotional period, including medication, membership, labs, shipping and refill timing.

For any GLP-1 offer, the FDA-approved versus compounded distinction matters. FDA-approved Wegovy and Zepbound have full prescribing information; compounded GLP-1 products are not FDA-approved and have different oversight. Hims may be a familiar brand, but users still need the same verification standard they would apply to any online provider.

Hims now shows several medication paths with monthly medication prices, including Wegovy pill and Foundayo pill from $149/month, Wegovy pen from $199/month, Zepbound vial or KwikPen from $299/month, and higher cash prices for some branded injectables. The important fine print is that those figures are medication-only prices where prescribed. The official Hims page says an active Weight Loss Membership is required, starting at $39 for the first month and renewing at $149/month, and that the membership is billed separately. That means a reader should not compare Hims against another program using only the medication card price. A fair comparison uses the total after the intro month: medication, membership, any lab needs, refill timing and cancellation rules.

Hims uses a broad menu, so the exact medication matters more than the brand name of the platform. Its page distinguishes FDA-approved weight-loss drugs such as Wegovy, Zepbound and Foundayo from Ozempic and Mounjaro, which are FDA-approved for type 2 diabetes and may only be prescribed when a licensed clinician decides the patient fits eligibility criteria. This is a key review point because many people use Ozempic as a shorthand for GLP-1 weight loss, but the label and access rules are not the same. The page should be read as an entry point to a clinician review, not a guarantee that a specific drug will be prescribed.

The value of Hims is convenience: intake, eligibility review, app-based tracking and access to a care team. The risk is that convenience can make the purchase feel simpler than the medical decision actually is. A strong Hims experience should include clear titration instructions, side-effect guidance, refill timing, what to do if nausea or constipation becomes hard to manage, and how to message a clinician when symptoms change. If you are already taking a GLP-1 and want to switch, Hims says it reviews medical history and current treatment rather than simply restarting care. That is useful, but it still depends on complete records and provider judgment.

Hims is strongest for users who want a mainstream telehealth interface and a menu of branded GLP-1 paths without starting with insurance paperwork. It is weaker for users who want the lowest possible total monthly cost or who dislike separate membership billing. The page is much more compelling now that it emphasizes FDA-approved options, but the reader still needs to verify the actual medication and recurring cost at checkout. Internally, compare Hims against Ro if insurance support matters, against Noom Med if behavior support matters, and against the guide for GLP-1 without insurance if you are paying cash.